Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

A Bold Endorsement for Oracle Shares Emerges Amid Market Uncertainty

Robert Sasse by Robert Sasse
November 28, 2025
in AI & Quantum Computing, Analysis, Tech & Software
0
Oracle Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

Oracle shares have navigated a volatile period recently, with investor confidence wavering over the substantial costs associated with its artificial intelligence initiatives. However, a decisive research note from Deutsche Bank, issued just before the Thanksgiving holiday, has dramatically shifted market sentiment. This development raises a critical question for investors: does the significant price decline of recent weeks represent a prime buying opportunity, or a potential value trap?

Quarterly Results to Provide Crucial Test

Market attention is now intensely focused on December 8, the date Oracle is scheduled to release its earnings for the second fiscal quarter. Wall Street is eagerly anticipating confirmation of the company’s cloud growth narrative and progress updates on new AI data center deployments. The analysis from Deutsche Bank has effectively recalibrated market expectations. The prevailing narrative is shifting away from concerns over expenditure, placing a renewed spotlight on the company’s untapped growth potential. Whether the bullish investors can maintain this momentum will be determined on earnings day.

This wave of optimism arrives at a pivotal moment. The stock faced substantial pressure throughout November, shedding more than 25% of its value over a 30-day window. Apprehension regarding the profitability of Oracle’s massive AI investments had soured investor morale. The stock’s recent significant upswing—marking a clear outperformance against the broader market—suggests a potential foundation for a sustained recovery may be forming.

Should investors sell immediately? Or is it worth buying Oracle?

Deutsche Bank Foresees Substantial Gains

The catalyst for this renewed positive outlook is a fresh analysis conducted by Deutsche Bank. Just ahead of the holiday, analyst Brad Zelnick reinforced his “Buy” recommendation and established a price target that implies an upside potential exceeding 80% from current trading levels. His conclusion is unambiguous: the market is profoundly undervaluing the software behemoth.

The stock’s valuation is a key factor attracting expert approval. Following the recent sell-off, the bank characterizes the present share price as a highly attractive entry point. The analysts present a compelling case built on several pillars:

  • Strategic Reset: The pullback from the 52-week high is viewed as a strategic acquisition window, particularly for institutional investors.
  • AI Infrastructure Foundation: The collaboration with OpenAI, coupled with the aggressive expansion of the Oracle Cloud Infrastructure (OCI) division, is creating durable value that the current market is overlooking.
  • Revenue Visibility: Despite skepticism surrounding high capital investment, the company’s Remaining Performance Obligations—a measure of future revenue from contracts—are trending upward, providing a solid base for future sales.

The overarching message from Deutsche Bank is that Oracle’s foundational strengths and strategic direction are not being fully appreciated, setting the stage for a potential re-rating.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 7 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

February 7, 2026
Guaranty Bancshares Stock
Analysis

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock
AI & Quantum Computing

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
Next Post
The Trade Desk Stock

The Trade Desk Stock: A Critical Juncture for Investors

Coca-Cola Stock

Coca-Cola Shares: Poised for Further Gains?

Salesforce Stock

Salesforce Shares: A Glimmer of Hope Amidst the Gloom?

Recommended

C3.ai Stock

Is C3.ai Stock Poised for a Rebound?

2 months ago
MMM stock news

Clarification on Hyperlink and Promotional Fees

2 years ago

XOMA Corporation Expands Portfolio with Acquisition of DSUVIA

2 years ago
Microsoft Stock

A Bold Bet: Peter Thiel’s Hedge Fund Doubles Down on Microsoft

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Trending

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

by SiterGedge
February 7, 2026
0

Avanos Medical is navigating a critical strategic transformation. The medical device firm is streamlining its operations to...

Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com